Ananth Sridhar is the chief operating officer of BridgeBio’s cardiorenal programs. Throughout his career, he has demonstrated a strong commitment to improving the lives of patients and has played a critical role in the development of four approved therapies for patients with significant unmet need.
Sridhar joined BridgeBio in 2018. In his current role, he leads two of the company’s most advanced programs, including recently approved Attruby (acoramidis) and encaleret, a Phase III investigational therapy in development for autosomal dominant hypocalcemia type 1 (ADH1). Prior to BridgeBio, Sridhar served in roles of increasing responsibility at Regeneron, most recently as senior manager, new products planning. His work during this time supported the approvals of blockbuster drugs including Praluent (alirocumab, for hypercholesterolemia), Dupixent (dupilumab, for atopic dermatitis) and Kevzara (sarilumab, for rheumatoid arthritis)—therapies that have impacted the lives of millions of patients and their families worldwide.
Outside of his professional career, Sridhar is committed to community improvement. In the Bay Area, he frequently volunteers with the San Francisco-Marin Food Bank and has organized an annual day of service called Stanford Beyond the Farm to bring together alumni to give back to the community. He also serves as a volunteer interviewer of applicants for Stanford, further underscoring his drive to identify potential in young talent and help them succeed.
Sridhar earned a Bachelor of Science with honors in chemical engineering from Stanford University and a Master of Business Administration from Harvard Business School.